Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of the Pediatric Infectious Diseases Society|August 17, 2023
Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina FasoAlphonse Ouedraogo, Amidou Diarra, Issa Nébié, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 11, 2020
Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina FasoSodiomon B Sirima, Alphonse Ouedraogo, Nouhoun Barry, et al.
American Journal of Human Genetics|September 25, 2012
A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiencyQing Zhou, Geun-Shik Lee, Jillian Brady, et al.
Research Square|March 17, 2025
An intranasal adjuvanted, recombinant influenza A/H5 vaccine candidate induces broad priming against diverse influenza A/H5N1 virus clades in a phase I randomized trial in healthy adultsMeagan E Deming, Franklin R Toapanta, Marcela Pasetti, et al.
Nature Communications|November 6, 2025
An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trialMeagan E Deming, Franklin R Toapanta, Marcela Pasetti, et al.
Human Vaccines & Immunotherapeutics|September 12, 2024
Single and two-dose typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian childrenNginache Nampota-Nkomba, Osward M Nyirenda, Victoria Mapemba, et al.
The Lancet. Global Health|August 12, 2022
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trialNginache Nampota-Nkomba, Osward M Nyirenda, Lameck Khonde, et al.
Lancet (London, England)|January 28, 2024
Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian childrenPriyanka D Patel, Yuanyuan Liang, James E Meiring, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 3, 2021
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trialSodiomon B Sirima, Alphonse Ouedraogo, Nouhoun Barry, et al.
The Journal of Allergy and Clinical Immunology|March 5, 2014
Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairmentYu Zhang, Xiaomin Yu, Mie Ichikawa, et al.
Pageof 3